Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Assess Safety and Tolerability, and Explore Efficacy of Leniolisib for Immune Dysregulation in Common Variable Immunodeficiency (CVID)

NCT06897358 is registered in ClinicalTrials.gov with Pharming Technologies B.V. as lead sponsor.

NCT NCT06897358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06897358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Assess Safety and Tolerability, and Explore Efficacy of Leniolisib for Immune Dysregulation in Common Variable Immunodeficiency (CVID)
Lead sponsor
Pharming Technologies B.V.
Phase
Phase 2
Overall status
Completed
Start date
February 12, 2025
Completion date
August 12, 2026
Enrollment
27 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

common variable immunodeficiency (cvid)